Publication: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

Post-hoc analyses to characterize changes in kidney function in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.